NEJM: Evaluating and Deploying Covid-19 Vaccines — The Importance of Transparency, Scientific Integrity, and Public Trust
The following article published in the New England Journal of Medicine, discusses the importance of adhering to well-established and transparent regulatory processes when it comes to approving a COVID-19 vaccine. Reassuring the public with robust scientific evaluation from independent bodies, without interference from governments for the purposes of political advantage, is essential to promote public confidence and ensure the success of vaccination programs.
Read the article in full here:
Halting the Oxford vaccine trial doesn't mean it's not safe- it shows they're following the right process
Due to a single event of an unexplained illness, the AstraZeneca Oxford group have announced a voluntary pause on all vaccinations across all sites of their COVID-19 vaccine candidate clinical trial. This pause will allow an independent committee to review the safety data and investigate the incident.
The following article, published in The Conversation, outlines how this halt doesn't necessarily indicate that the vaccine is not safe, but reflects the robust processes for clinical trials. It is important to recognise that whilst these clinical trials are moving at pandemic speed, safety is not being compromised.
2020 influenza vaccines- it's not too late to get vaccinated
Influenza disease can occur at any time of year and vaccination is recommended for everyone over 6-months of age. Certain patient groups are eligible for funded influenza vaccines on the National Immunisation Program (NIP). It is also available to purchase for those who do not meet funding criteria.
For further information on influenza vaccination in 2020 please refer to the following resources:
Australian Government Department of Health: 2020 influenza vaccines- it's not too late to get vaccinated
MVEC: Influenza vaccine recommendations
MVEC: Influenza vaccine- Frequently asked questions
Africa declared free of wild polio
After 4 years without a case of wild polio, the African region has been declared free of wild poliovirus. MVEC congratulates the efforts of everyone involved in accomplishing such a tremendous achievement which has been described by WHO director-general Dr Tedros Adhanom Ghebreyesus as "one of the greatest public health achievements of our time". This milestone means that Afghanistan and Pakistan are the only 2 countries worldwide who continue to see wild poliovirus transmission.
To read more on this remarkable effort please follow the links:
Africa kicks out wild polio
WHO: Global polio eradication initiative applauds WHO African region for wild polio-free certification
Zostavax safety advice: not to be administered to people with compromised immune function
The Therapeutic Goods Administration (TGA) have issued a reminder that Zostavax® vaccine should not be administered to people with compromised immune function. Vaccination in this patient group is contraindicated and can result in infection with the vaccine virus causing mild to severe complications (including death).
Further details on the alert can be seen here: TGA: Zostavax® vaccine
For more information on Zostavax® and access to the Zostavax® GP decision aid please review the MVEC pages below:
MVEC: Zoster
MVEC: Zoster vaccine (Zostavax®) FAQ's
The use of foetal tissue in vaccine development
There has been attention in the media recently regarding the use of foetal cell lines by the Oxford Vaccine Group to develop their COVID-19 vaccine candidate. Cell lines are currently used to manufacture many vaccines including varicella, hepatitis A, rabies and MMR vaccines.
The below information from the Children's Hospital of Philadelphia (CHoP) discusses the background behind using these cell lines in vaccine development as well as any potential ethical or religious concerns surrounding this.
Vaccine ingredients- Fetal tissues
The RCH Immunisation Service: Drive-through clinic is now open
To support families in continuing to receive scheduled vaccinations during the COVID-19 pandemic, the RCH Immunisation Service has just opened its own immunisation drive-through clinic. Additional precautions have been implemented to ensure the safety of all patients, families and staff. Access to medical care remains an essential service during this time and staying up to date with scheduled immunisations is encouraged.
The drive-through clinic will operate on Tuesdays and Wednesdays from 9am - 1pm until September 15.
Bookings for the drive-through clinic are mandatory and can be made by contacting the immunisation team via this link.
HealthEd podcast featuring Associate Professor Nigel Crawford
MVEC's Associate Professor Nigel Crawford was recently a guest speaker on the HealthEd podcast series Going Viral. In this podcast, Nigel discusses the COVID-19 vaccine, its access equity, safety and manufacture; as well as antibody responses following COVID-19 disease and how this may impact our vaccine strategy.
To listen to this podcast please follow the link
NDTV speak to Professor Kanta Subbarao, Director of WHO Collaborating Centre for Reference and Research on Influenza
Questions and answers about COVID-19 vaccines
The Vaccine Education Center (VEC) at the Children's Hospital of Philadelphia (CHoP) has recently launched a new resource page answering common questions related to the development and safety of COVID-19 vaccines. Readers are also encouraged to submit their own questions directly to the VEC team for response.
To access this initiative please follow the link here